Sotio Opens Beijing Lab for Cancer Immunotherapy

Sotio, a Czech biotech, has opened a Beijing lab from which it will produce DCVAC, the company’s autologous cellular immunotherapy for cancer. At the outset, Sotio will make products for patients with prostate cancer, who will be enrolled in the company’s global Phase III clinical trial. Sotio’s technology is built on using a person’s dendritic cells, activated by tumor antigens, to treat cancer and autoimmune diseases. The company already has a lab in Prague. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.